Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Neurofibrosarcoma 3Neurofibromatosis 1 3Sarcoma 2Sarcoma, Kaposi 1Acquired Immunodeficiency Syndrome 1AIDS-related Kaposi sarcoma 1

Interventions

Doxorubicin 142Ifosfamide 85Radiotherapy 82Cyclophosphamide 72Gemcitabine 63Filgrastim 54pembrolizumab 43pazopanib 40Etoposide 39Docetaxel 39Vincristine 37Trabectedin 37Cisplatin 35Nivolumab 32Magnetic Resonance Spectroscopy 26Irinotecan 26Carboplatin 25Surgical Procedures, Operative 24Temozolomide 23Radiation 22Ipilimumab 22Bevacizumab 20Blood Specimen Collection 19Granulocyte Colony-Stimulating Factor 18Biopsy 18eribulin 17anlotinib 17Sirolimus 17Mesna 17Melphalan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma × AZD 6244 × Sarcoma × Clear all
NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

University of Alabama at Birmingham

Phase 2 Not yet recruiting
41 enrolled
CNSSarcoma

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

NCT01206140 2015-10-05

Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Completed
70 enrolled 8 charts
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡